ONCOLOGÍA MÉDICA

1991

Artículos

Ausejo Segura M, Cruz Cruz T, Grávalos C, García Marco D, Alberola Gómez-Escobar C, Herreros de Tejada A. Participation of a pharmacy service in a home chemotherapy programme. Farm Clín. 1991;8(2):184-8

.

1992

Artículos

Moreno Cerro AM, Martínez Tello FJ, De Juanes Pardo JR, Cortés-Funes H. Registro de tumores del Hospital 12 de Octubre. Estudio retrospectivo de los tumores malignos durante los años 1987-1989. Oncologia. 1992;15(9):404-13

.

1993

Artículos

Mayordomo JI, Guerra JM, Guijarro C, García Prats MD, Gómez A, López Brea M, et al. Neoplasms of unknown primary site: a clinicopathological study of autopsied patients. Tumori. 1993;79(5):321-4.

Paz Ares L, Lianes P, Díaz Puente M, Rivera F, Passas J, Costas P, et al. CMV front-line chemotherapy in transitional bladder carcinoma. Ann Oncol. 1993;4(2):147-50

Congresos

Paz-Ares L, Lianes P, Cortés-Funes H. Late relapses in advanced Malignant Germ Cell Tumours (MGCT) treated with cisplatin based chemotherapy [doi]. En: Jones WG, Harnden P, Appleyard I, eds. Advances in the Biosciences Germ Cell tumours III. Exeter: Pergamon; 1993. p. 273-4 [Proceedings of the Third Germ Cell Tumour Conference Held (3. Leeds. 1993)]

Paz-Ares L, López Brea M, Rivera F, P Lianes P, Cortés-Funes H. Salvage therapy in refractory/relapsed germ cell tumours: etoposide, iphosphamide and cisplatin (VIP) [doi]. En: Jones WG, Harnden P, Appleyard I, eds. Advances in the Biosciences Germ Cell tumours III. Exeter: Pergamon; 1993. p. 439-440 [Proceedings of the Third Germ Cell Tumour Conference Held (3. Leeds. 1993)]

.

1994

Artículos

Gil F, Lianes P, Kash K.M, Holland JC. Soporte psicológico, consejo genético y alto riesgo hereditario de cáncer. Oncologia. 1994;17(11):43-8

Mayordomo JI, Paz Ares L, Rivera F, López Brea M, López Martín E, Mendiola C, et al. Ovarian and extragonadal malignant germ-cell tumors in females: a single-institution experience with 43 patients. Ann Oncol. 1994;5(3):225-31.

Mayordomo Cámara JI, Guerra Vales JM. Hacia una evaluación de los pacientes con cáncer de origen desconocido basada en el diagnóstico histológico. Propuesta de un algoritmo. Med Clin (Barc). 1994;102(11):423-6.

Paz Ares L, Lianes P, Cortés Funes H. The management of non-seminomatous germ cell tumours (GCT). Ann Oncol. 1994;5(5):457-62.

.

1995

Artículos

Colomer R. Genes en cáncer de mama: aplicaciones actuales y futuras. Revis Cancer. 1995;9(4):144-52

Hitt R, Hornedo J, Colomer R, Mendiola C, Brandáriz A, Sevilla E, et al. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results. Semin Oncol. 1995;22(6 Suppl 15):50-4

Hornedo J, Hidalgo M, Trigo M. Indicaciones de los factores de crecimiento hematopoyético en el manejo de las complicaciones infecciosas de la quimioterapia. Inflam Regul Crecim Cel. 1995;6(Nº Espec.):55-60

Mayordomo JI, Rivera F, Díaz Puente MT, Lianes P, Colomer R, López Brea M, et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst. 1995;87(11):803-8

Ruiz A, Lianes P, Cortés-Funes H. Quimioterapia a altas dosis en el tratamiento de los tumores de células germinales. Situación actual, perspectivas futuras. Oncologia. 1995;18(11):28-38

.

1996

Artículos

Domínguez Ortega L, Cubedo Cervera R, Cortés Funés H, Díaz Gállego E. Sleep protects against chemotherapy induced emesis. Cancer. 1996;77(8):1566-70

Hidalgo M, Benito J, Colomer R, Paz-Ares L. Recall reaction of a severe local peripheral neuropathy after paclitaxel extravasation. J Natl Cancer Inst. 1996;88(18):1320 [doi]

Hidalgo M, Lumbreras C, Aguado JM. Síndromes linfoproliferativos asociados al virus de Epstein-Barr en receptores de trasplante de órganos. Med Clin (Barc). 1996;107(8):310-6

Hidalgo M, Paz-Ares L. Cáncer y SIDA: una extraña pareja. Med Clin (Barc). 1996;106(17):659-60

Hornedo J, Hidalgo M, Trigo JM. Indicaciones de los factores de crecimiento hematopoyético en el manejo de las complicaciones infecciosas de la quimioterapia. Inflam Regul Crecim Cel. 1996;7(2):106-10

.

1997

Artículos

Colomer R, Aparicio J, Montero S, Guzmán C, Larrodera L, Cortés-Funes H. Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma. Br J Cancer. 1997;76(9):1215-20.

Cortés-Funes H, Aisner J. Paclitaxel in head and neck cancer and other tumor types: chairmen’s introduction. Semin Oncol. 1997;24(1 Suppl 2):S51-7

Fernández Miranda C, Schoebel N, Angulo A, Paz-Ares L, Lianes P, Del Palacio A. Evolución a largo plazo de los lípidos séricos y del índice de masa corporal en varones con cáncer testicular tratados con quimioterapia. Rev Clin Esp. 1997;197(7):490-3

García Carbonero R, Hidalgo M, Paz-Ares L, Calzas J, Gómez H, Guerra JA, et al. Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer. J Clin Oncol. 1997;15(10):3178-84

Hidalgo M, Hornedo J, Lumbreras C, Trigo JM, Gómez C, Perea S, et al. Lack of ability of ciprofloxacin-rifampin prophylaxis to decrease infection-related morbidity in neutropenic patients given cytotoxictherapy and peripheral blood stem cell transplants. Antimicrob Agents Chemother. 1997;41(5):1175-7.

Hidalgo M, Paz-Ares L, Rivera F, Lianes P, Huidobro G, Ruiz A, et al. Mediastinal non-seminomatous germ cell tumours (MNSGCT) treated with cisplatin-based combination chemotherapy. Ann Oncol. 1997;8(6):555-9.

Hitt R, Hornedo J, Colomer R, Hidalgo M, Brandáriz A, Peña M, et al. Study of escalating doses of paclitaxel plus cisplatin in patients with inoperable head and neck cancer. Semin Oncol. 1997;24(1 Suppl2):S58-64.

Hitt R, Paz Ares L, Hidalgo M, Colomer R, Brandáriz A, Peña M, et al. Phase I/II study of paclitaxel/cisplatin as first-line therapy for locally advanced head and neck cancer. Semin Oncol. 1997;24(6 Suppl 19):S20-24

International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. . J Clin Oncol. 1997;15(2):594-603 [doi]

Paz Ares L, Lahuerta J, Montes A. Tratamiento intensivo del mieloma múltiple con soporte de progenitores de la hematopoyesis. Med Clin (Barc). 1997;108(6):226-9.

Wasserman E, Hidalgo M, Hornedo J, Cortés-Funes H. Octreotide (SMS 201-995) for hematopoietic support-dependent high-dose chemotherapy (HSD-HDC)-related diarrhoea: dose finding study and evaluation of efficacy. Bone Marrow Transplant. 1997;20(9):711-4.

.

1998

Artículos

Calzas J, Lianes P, Cortés Funes H. Patología del corazón de origen extracardiaco (VII). Corazón y neoplasias. Rev Esp Cardiol. 1998;51(4):314-31.

Castellano D, Lianes P, Paz Ares L, Hidalgo M, Guerra JA, Gómez Martín C, et al. A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small-cell lung cancer. Ann Oncol. 1998;9(4):457-9.

García Carbonero R, Paz Ares L, Arcediano A, Lahuerta J, Bartolomé A, Cortés Funes H. Favorable prognosis after late relapse of Hodgkin’s disease. Cancer. 1998;83(3):560-5.

Hidalgo M, Mendiola C, López Vega JM, Castellano D, Méndez M, Batiste Alentón E, et al. A multicenter randomized phase II trial of granulocyte-colony stimulating factor-supported, platinum-based chemotherapy with flexible midcycle cisplatin administration in patients with advanced ovarian carcinoma. PSAMOMA Cooperative Group, Spain. Cancer. 1998;83(4):719-25.

Hitt R, Castellano D, Hidalgo M, García Carbonero R, Peña M, Brandáriz A, et al. Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck. Ann Oncol. 1998;9(12):1347-9.

Montero S, Guzmán C, Cortés Funes H, Colomer R. Angiogenin expression and prognosis in primary breast carcinoma. Clin Cancer Res. 1998;4(9):2161-8

Ramia JM, Alcalde J, Dhimes P, Cubedo R. Metastasis from choriocarcinoma of the mediastinum producing acute appendicitis. Dig Dis Sci. 1998;43(2):332-4

.

1999

Artículos

Hidalgo M, Castellano D, Paz-Ares L, Grávalos C, Díaz Puente M, Hitt R, Alonso S, Cortés Funes H. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol. 1999;17(2):585-92.

Hidalgo M, Hornedo J, Lumbreras C, Trigo JM, Colomer R, Perea S, Gómez C, Ruiz A, García Carbonero R, Cortés Funes H. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer. 1999;85(1):213-9

Lassaletta L, Brandáriz JA, Benito A, Gómez C, Ballestín C, Hitt R, De la Cruz J, Álvarez-Vicent JJ. Detección de proteína p53 en tumores avanzados de cabeza y cuello. Acta Otorrinolaringol Esp. 1999;50(8):613-8

Perea S, Hidalgo M, Arcediano A, Ramos MJ, Gómez C, Hornedo J, Lumbreras C, Folgueira D, Corté Funes H, Rodríguez Noriega A. Incidence and clinical impact of fluoroquinolone-resistant Escherichia coli in the faecal flora of cáncer patients treated with high dose chemotherapy and ciprofloxacin prophylaxis. J Antimicrob Chemother. 1999;44(1):117-20

Valentín V, Murillo M, Azcoitia B, Ausejo M, Carretero Y, Cayuela PP. Control del dolor y prescripción de medicamentos en un programa de atención domiciliaria al paciente oncológico terminal. Oncologia. 1999;22(1):49-56

.

2000

Artículos

Aebi S, Gelber S, Castiglione-Gertsch M, Gelber RD, Collins J, Thürlimann B, et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet. 2000;355(9218):1869-74 [doi

Bellmunt J, Guillem V, Paz-Ares L, González Larriba JL, Carles J, Albanell J, et al. Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer. Eur J Cancer. 2000;36(Suppl 2):17-25 [doi]

Bellmunt J, Guillem V, Paz-Ares L, González-Larriba JL, Carles J, Batiste-Alentorn E, et al. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J Clin Oncol. 2000;18(18):3247-55 [doi]

Castellano D, Hitt R, Cortés Funes H, Romero A, Rodríguez Peralto JL. Side effects of chemotherapy. Case 2. Radiation recall reaction induced by gemcitabine. J Clin Oncol. 2000;18(3):695-6

Colomer R, Llombart A, Lluch A, Ojeda B, Barnadas A, Carañana V, Fernández Y, De Paz L, Guillem V, Alonso S. Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: preliminary results of a phase II trial. Semin Oncol. 2000;27(1 Suppl 2):20-4

Colomer R, Montero S, Lluch A, Ojeda B, Barnadas A, Casado A, Massutí B, Cortés Funes H, Lloveras B. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res. 2000;6(6):2356-62

Gómez Martín C, Solá C, Hornedo J, Perea S, Lumbreras C, Valentí V, Arcediano A, Rodríguez M, Salazar R, Cortés Funes H, Hidalgo M. Rifampin does not improve the efficacy of quinolone antibacterial prophylaxis in neutropenic cáncer patients: results of a randomized clinical trial. J Clin Oncol. 2000;18(10):2126-34

Lluch A, Ojeda B, Colomer R, Barnadas A, Massuti B, Casado A, et al. Doxorubicin and paclitaxel in advanced breast carcinoma: importance of prior adjuvant anthracycline therapy. Cancer. 2000;89(11):2169-75 [doi

Pronk LC, Vasey P, Sparreboom A, Reigner B, Planting AS, Gordon RJ, et al. A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. Br J Cancer. 2000;83(1):22-9 [doi

Trigo JM, Tabernero JM, Paz Ares L, García Llano JL, Mora J, Lianes P, Esteban E, Salazar R, López López JJ, Cortés Funes H. Tumor markers at the time of recurrence in patients with germ cell tumors. Cancer. 2000;88(1):162-8

Valentí Moreno V, Tabernero Caturla J, Villavicencio Mavrich H, Paz-Ares L, Santomé Couto L. Diagnóstico y manejo del carcinoma “in situ” testicular [Diagnosis and management of carcinoma in situ of the testis]. Arch Esp Urol. 2000;53(6):443-6